Haleon plc
Haleon plc HLN Peers
See (HLN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HLN | $11.07 | -0.49% | 50B | 25.73 | $0.43 | +1.52% |
| ZTS | $170.01 | +0.83% | 75.7B | 30.52 | $5.57 | +1.10% |
| TAK | $14.96 | -0.23% | 47.1B | 65.02 | $0.23 | +3.94% |
| TEVA | $17.77 | +3.01% | 20.4B | -15.45 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.54 | +0.07% | 12.9B | 19.67 | $0.79 | +0.62% |
| NBIX | $125.34 | +0.59% | 12.4B | 42.49 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $8.71 | +2.96% | 10.2B | -2.74 | -$3.18 | +5.53% |
| RGC | $695.00 | +11.21% | 9B | -2171.87 | -$0.32 | N/A |
Stock Comparison
HLN vs ZTS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ZTS has a market cap of 75.7B. Regarding current trading prices, HLN is priced at $11.07, while ZTS trades at $170.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ZTS's P/E ratio is 30.52. In terms of profitability, HLN's ROE is +0.09%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, HLN is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs TAK Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TAK has a market cap of 47.1B. Regarding current trading prices, HLN is priced at $11.07, while TAK trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TAK's P/E ratio is 65.02. In terms of profitability, HLN's ROE is +0.09%, compared to TAK's ROE of +0.04%. Regarding short-term risk, HLN is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs TEVA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TEVA has a market cap of 20.4B. Regarding current trading prices, HLN is priced at $11.07, while TEVA trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TEVA's P/E ratio is -15.45. In terms of profitability, HLN's ROE is +0.09%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ITCI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HLN is priced at $11.07, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HLN's ROE is +0.09%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, HLN is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs RDY Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, RDY has a market cap of 12.9B. Regarding current trading prices, HLN is priced at $11.07, while RDY trades at $15.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas RDY's P/E ratio is 19.67. In terms of profitability, HLN's ROE is +0.09%, compared to RDY's ROE of +0.18%. Regarding short-term risk, HLN is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs NBIX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, NBIX has a market cap of 12.4B. Regarding current trading prices, HLN is priced at $11.07, while NBIX trades at $125.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas NBIX's P/E ratio is 42.49. In terms of profitability, HLN's ROE is +0.09%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, HLN is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CTLT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HLN is priced at $11.07, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HLN's ROE is +0.09%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, HLN is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs VTRS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, VTRS has a market cap of 10.2B. Regarding current trading prices, HLN is priced at $11.07, while VTRS trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas VTRS's P/E ratio is -2.74. In terms of profitability, HLN's ROE is +0.09%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs RGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, RGC has a market cap of 9B. Regarding current trading prices, HLN is priced at $11.07, while RGC trades at $695.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas RGC's P/E ratio is -2171.87. In terms of profitability, HLN's ROE is +0.09%, compared to RGC's ROE of -0.25%. Regarding short-term risk, HLN is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ELAN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ELAN has a market cap of 6.9B. Regarding current trading prices, HLN is priced at $11.07, while ELAN trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ELAN's P/E ratio is 18.56. In terms of profitability, HLN's ROE is +0.09%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LNTH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, HLN is priced at $11.07, while LNTH trades at $81.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas LNTH's P/E ratio is 23.23. In terms of profitability, HLN's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HLN is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PRGO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PRGO has a market cap of 3.6B. Regarding current trading prices, HLN is priced at $11.07, while PRGO trades at $26.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PRGO's P/E ratio is -21.80. In terms of profitability, HLN's ROE is +0.09%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, HLN is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AMRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AMRX has a market cap of 3.5B. Regarding current trading prices, HLN is priced at $11.07, while AMRX trades at $7.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AMRX's P/E ratio is -190.50. In terms of profitability, HLN's ROE is +0.09%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALVOW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ALVOW has a market cap of 3.2B. Regarding current trading prices, HLN is priced at $11.07, while ALVOW trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ALVOW's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.09%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, HLN is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALVO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ALVO has a market cap of 3.2B. Regarding current trading prices, HLN is priced at $11.07, while ALVO trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ALVO's P/E ratio is 28.81. In terms of profitability, HLN's ROE is +0.09%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, HLN is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HCM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, HLN is priced at $11.07, while HCM trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas HCM's P/E ratio is 76.75. In terms of profitability, HLN's ROE is +0.09%, compared to HCM's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BGM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, BGM has a market cap of 2.5B. Regarding current trading prices, HLN is priced at $11.07, while BGM trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas BGM's P/E ratio is -68.84. In terms of profitability, HLN's ROE is +0.09%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HLN is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DCPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HLN is priced at $11.07, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HLN's ROE is +0.09%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, HLN is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs EMBCV Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HLN is priced at $11.07, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.09%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SUPN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, HLN is priced at $11.07, while SUPN trades at $33.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SUPN's P/E ratio is 29.86. In terms of profitability, HLN's ROE is +0.09%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BHC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, HLN is priced at $11.07, while BHC trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas BHC's P/E ratio is -39.62. In terms of profitability, HLN's ROE is +0.09%, compared to BHC's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs INDV Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, INDV has a market cap of 1.8B. Regarding current trading prices, HLN is priced at $11.07, while INDV trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas INDV's P/E ratio is -281.40. In terms of profitability, HLN's ROE is +0.09%, compared to INDV's ROE of -0.01%. Regarding short-term risk, HLN is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TARO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HLN is priced at $11.07, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TARO's P/E ratio is 30.05. In terms of profitability, HLN's ROE is +0.09%, compared to TARO's ROE of +0.02%. Regarding short-term risk, HLN is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs EVO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, HLN is priced at $11.07, while EVO trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EVO's P/E ratio is -6.04. In terms of profitability, HLN's ROE is +0.09%, compared to EVO's ROE of -0.22%. Regarding short-term risk, HLN is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs ANIP Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ANIP has a market cap of 1.3B. Regarding current trading prices, HLN is priced at $11.07, while ANIP trades at $61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ANIP's P/E ratio is -52.51. In terms of profitability, HLN's ROE is +0.09%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, HLN is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DVAX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, HLN is priced at $11.07, while DVAX trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas DVAX's P/E ratio is -20.48. In terms of profitability, HLN's ROE is +0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HLN is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AMPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, HLN is priced at $11.07, while AMPH trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AMPH's P/E ratio is 9.42. In terms of profitability, HLN's ROE is +0.09%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, HLN is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PCRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PCRX has a market cap of 1.2B. Regarding current trading prices, HLN is priced at $11.07, while PCRX trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PCRX's P/E ratio is -11.59. In terms of profitability, HLN's ROE is +0.09%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, HLN is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HROW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, HLN is priced at $11.07, while HROW trades at $29.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas HROW's P/E ratio is -48.51. In terms of profitability, HLN's ROE is +0.09%, compared to HROW's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PAHC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PAHC has a market cap of 976M. Regarding current trading prices, HLN is priced at $11.07, while PAHC trades at $24.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PAHC's P/E ratio is 30.87. In terms of profitability, HLN's ROE is +0.09%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, HLN is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs COLL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, COLL has a market cap of 970.7M. Regarding current trading prices, HLN is priced at $11.07, while COLL trades at $30.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas COLL's P/E ratio is 24.75. In terms of profitability, HLN's ROE is +0.09%, compared to COLL's ROE of +0.19%. Regarding short-term risk, HLN is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AVDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AVDL has a market cap of 940.3M. Regarding current trading prices, HLN is priced at $11.07, while AVDL trades at $9.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AVDL's P/E ratio is -37.38. In terms of profitability, HLN's ROE is +0.09%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, HLN is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PETQ Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HLN is priced at $11.07, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HLN's ROE is +0.09%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, HLN is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs CRON Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CRON has a market cap of 763.1M. Regarding current trading prices, HLN is priced at $11.07, while CRON trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CRON's P/E ratio is 14.14. In terms of profitability, HLN's ROE is +0.09%, compared to CRON's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EOLS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EOLS has a market cap of 647.3M. Regarding current trading prices, HLN is priced at $11.07, while EOLS trades at $10.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EOLS's P/E ratio is -11.28. In terms of profitability, HLN's ROE is +0.09%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, HLN is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BDSI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HLN is priced at $11.07, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HLN's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HLN is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs EMBC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EMBC has a market cap of 572.2M. Regarding current trading prices, HLN is priced at $11.07, while EMBC trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EMBC's P/E ratio is 11.00. In terms of profitability, HLN's ROE is +0.09%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SIGA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SIGA has a market cap of 430.8M. Regarding current trading prices, HLN is priced at $11.07, while SIGA trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SIGA's P/E ratio is 9.00. In terms of profitability, HLN's ROE is +0.09%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, HLN is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TLRY Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TLRY has a market cap of 416M. Regarding current trading prices, HLN is priced at $11.07, while TLRY trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TLRY's P/E ratio is -0.37. In terms of profitability, HLN's ROE is +0.09%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, HLN is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs KMDA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, KMDA has a market cap of 393.3M. Regarding current trading prices, HLN is priced at $11.07, while KMDA trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas KMDA's P/E ratio is 24.43. In terms of profitability, HLN's ROE is +0.09%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, HLN is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ORGO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ORGO has a market cap of 384.4M. Regarding current trading prices, HLN is priced at $11.07, while ORGO trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ORGO's P/E ratio is -18.94. In terms of profitability, HLN's ROE is +0.09%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, HLN is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EBS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EBS has a market cap of 360.4M. Regarding current trading prices, HLN is priced at $11.07, while EBS trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EBS's P/E ratio is -2.57. In terms of profitability, HLN's ROE is +0.09%, compared to EBS's ROE of -0.27%. Regarding short-term risk, HLN is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AQST Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AQST has a market cap of 353.6M. Regarding current trading prices, HLN is priced at $11.07, while AQST trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AQST's P/E ratio is -6.14. In terms of profitability, HLN's ROE is +0.09%, compared to AQST's ROE of +1.07%. Regarding short-term risk, HLN is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CGC has a market cap of 353M. Regarding current trading prices, HLN is priced at $11.07, while CGC trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CGC's P/E ratio is -0.42. In terms of profitability, HLN's ROE is +0.09%, compared to CGC's ROE of -1.13%. Regarding short-term risk, HLN is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SNDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SNDL has a market cap of 339.6M. Regarding current trading prices, HLN is priced at $11.07, while SNDL trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SNDL's P/E ratio is -4.40. In terms of profitability, HLN's ROE is +0.09%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, HLN is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TKNO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TKNO has a market cap of 316.9M. Regarding current trading prices, HLN is priced at $11.07, while TKNO trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TKNO's P/E ratio is -12.89. In terms of profitability, HLN's ROE is +0.09%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, HLN is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ACB Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ACB has a market cap of 313.9M. Regarding current trading prices, HLN is priced at $11.07, while ACB trades at $5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ACB's P/E ratio is 28.60. In terms of profitability, HLN's ROE is +0.09%, compared to ACB's ROE of +0.02%. Regarding short-term risk, HLN is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ALIM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HLN is priced at $11.07, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HLN's ROE is +0.09%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, HLN is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs ZYBT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ZYBT has a market cap of 280.1M. Regarding current trading prices, HLN is priced at $11.07, while ZYBT trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ZYBT's P/E ratio is 98.50. In terms of profitability, HLN's ROE is +0.09%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, HLN is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LNDC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HLN is priced at $11.07, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HLN's ROE is +0.09%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, HLN is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LFCR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, LFCR has a market cap of 253.6M. Regarding current trading prices, HLN is priced at $11.07, while LFCR trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas LFCR's P/E ratio is -4.72. In terms of profitability, HLN's ROE is +0.09%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, HLN is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ESPR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ESPR has a market cap of 241.8M. Regarding current trading prices, HLN is priced at $11.07, while ESPR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ESPR's P/E ratio is -1.44. In terms of profitability, HLN's ROE is +0.09%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, HLN is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TYHT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HLN is priced at $11.07, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HLN's ROE is +0.09%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, HLN is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs OGI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, OGI has a market cap of 182.1M. Regarding current trading prices, HLN is priced at $11.07, while OGI trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas OGI's P/E ratio is 10.46. In terms of profitability, HLN's ROE is +0.09%, compared to OGI's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs REPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HLN is priced at $11.07, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas REPH's P/E ratio is -8.04. In terms of profitability, HLN's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HLN is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DERM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, DERM has a market cap of 171.9M. Regarding current trading prices, HLN is priced at $11.07, while DERM trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas DERM's P/E ratio is -19.95. In terms of profitability, HLN's ROE is +0.09%, compared to DERM's ROE of -0.52%. Regarding short-term risk, HLN is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BIOA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, BIOA has a market cap of 159.5M. Regarding current trading prices, HLN is priced at $11.07, while BIOA trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas BIOA's P/E ratio is -2.25. In terms of profitability, HLN's ROE is +0.09%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, HLN is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs THTX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, THTX has a market cap of 118.6M. Regarding current trading prices, HLN is priced at $11.07, while THTX trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas THTX's P/E ratio is -36.86. In terms of profitability, HLN's ROE is +0.09%, compared to THTX's ROE of +0.16%. Regarding short-term risk, HLN is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CRDL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CRDL has a market cap of 116.5M. Regarding current trading prices, HLN is priced at $11.07, while CRDL trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CRDL's P/E ratio is -4.15. In terms of profitability, HLN's ROE is +0.09%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, HLN is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SCTL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HLN is priced at $11.07, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HLN's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HLN is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs PROC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, HLN is priced at $11.07, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PROC's P/E ratio is 1.53. In terms of profitability, HLN's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HLN is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs IRWD Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, IRWD has a market cap of 98.2M. Regarding current trading prices, HLN is priced at $11.07, while IRWD trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas IRWD's P/E ratio is -3.19. In terms of profitability, HLN's ROE is +0.09%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, HLN is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs OPTN Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HLN is priced at $11.07, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HLN's ROE is +0.09%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, HLN is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs ZOM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HLN is priced at $11.07, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HLN's ROE is +0.09%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, HLN is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs GRVI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HLN is priced at $11.07, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HLN's ROE is +0.09%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, HLN is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs CPIX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CPIX has a market cap of 87.1M. Regarding current trading prices, HLN is priced at $11.07, while CPIX trades at $5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CPIX's P/E ratio is -24.25. In terms of profitability, HLN's ROE is +0.09%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, HLN is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs INCR Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, INCR has a market cap of 70.7M. Regarding current trading prices, HLN is priced at $11.07, while INCR trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas INCR's P/E ratio is -3.57. In terms of profitability, HLN's ROE is +0.09%, compared to INCR's ROE of -0.07%. Regarding short-term risk, HLN is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ZYNE Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HLN is priced at $11.07, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HLN's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HLN is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SSIC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HLN is priced at $11.07, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HLN's ROE is +0.09%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, HLN is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ASRT Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ASRT has a market cap of 63.4M. Regarding current trading prices, HLN is priced at $11.07, while ASRT trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ASRT's P/E ratio is -2.07. In terms of profitability, HLN's ROE is +0.09%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, HLN is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs VLNS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HLN is priced at $11.07, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HLN's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, HLN is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SXTC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SXTC has a market cap of 54.4M. Regarding current trading prices, HLN is priced at $11.07, while SXTC trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SXTC's P/E ratio is 0.02. In terms of profitability, HLN's ROE is +0.09%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, HLN is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs JUPW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HLN is priced at $11.07, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HLN's ROE is +0.09%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, HLN is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs QNTM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, QNTM has a market cap of 45M. Regarding current trading prices, HLN is priced at $11.07, while QNTM trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas QNTM's P/E ratio is -1.17. In terms of profitability, HLN's ROE is +0.09%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, HLN is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs QLI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HLN is priced at $11.07, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas QLI's P/E ratio is -4.92. In terms of profitability, HLN's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HLN is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs SCYX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SCYX has a market cap of 35.8M. Regarding current trading prices, HLN is priced at $11.07, while SCYX trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SCYX's P/E ratio is -1.64. In terms of profitability, HLN's ROE is +0.09%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, HLN is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs RMTI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, RMTI has a market cap of 34.9M. Regarding current trading prices, HLN is priced at $11.07, while RMTI trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas RMTI's P/E ratio is -102.00. In terms of profitability, HLN's ROE is +0.09%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, HLN is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs HEXO Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HLN is priced at $11.07, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HLN's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HLN is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs KALA Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, KALA has a market cap of 26.5M. Regarding current trading prices, HLN is priced at $11.07, while KALA trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas KALA's P/E ratio is -0.55. In terms of profitability, HLN's ROE is +0.09%, compared to KALA's ROE of -3.69%. Regarding short-term risk, HLN is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs EGRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, EGRX has a market cap of 25.9M. Regarding current trading prices, HLN is priced at $11.07, while EGRX trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas EGRX's P/E ratio is 2.35. In terms of profitability, HLN's ROE is +0.09%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, HLN is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs CYTH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HLN is priced at $11.07, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HLN's ROE is +0.09%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, HLN is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for HLN.
HLN vs IXHL Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, IXHL has a market cap of 16.8M. Regarding current trading prices, HLN is priced at $11.07, while IXHL trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas IXHL's P/E ratio is -0.15. In terms of profitability, HLN's ROE is +0.09%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, HLN is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs DRRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, DRRX has a market cap of 16.8M. Regarding current trading prices, HLN is priced at $11.07, while DRRX trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas DRRX's P/E ratio is -1.20. In terms of profitability, HLN's ROE is +0.09%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, HLN is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs GELS Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, GELS has a market cap of 16M. Regarding current trading prices, HLN is priced at $11.07, while GELS trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas GELS's P/E ratio is -7.04. In terms of profitability, HLN's ROE is +0.09%, compared to GELS's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TXMD Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TXMD has a market cap of 14.9M. Regarding current trading prices, HLN is priced at $11.07, while TXMD trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TXMD's P/E ratio is -6.79. In terms of profitability, HLN's ROE is +0.09%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, HLN is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs PRPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, PRPH has a market cap of 14.6M. Regarding current trading prices, HLN is priced at $11.07, while PRPH trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas PRPH's P/E ratio is -0.16. In terms of profitability, HLN's ROE is +0.09%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, HLN is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs ACRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HLN is priced at $11.07, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HLN's ROE is +0.09%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, HLN is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs FLGC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, FLGC has a market cap of 14.4M. Regarding current trading prices, HLN is priced at $11.07, while FLGC trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas FLGC's P/E ratio is -0.67. In terms of profitability, HLN's ROE is +0.09%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, HLN is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs COSM Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, COSM has a market cap of 13.9M. Regarding current trading prices, HLN is priced at $11.07, while COSM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas COSM's P/E ratio is -0.44. In terms of profitability, HLN's ROE is +0.09%, compared to COSM's ROE of -0.51%. Regarding short-term risk, HLN is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AYTU Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AYTU has a market cap of 12.3M. Regarding current trading prices, HLN is priced at $11.07, while AYTU trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AYTU's P/E ratio is -1.34. In terms of profitability, HLN's ROE is +0.09%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, HLN is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs TLPH Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, TLPH has a market cap of 10.5M. Regarding current trading prices, HLN is priced at $11.07, while TLPH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas TLPH's P/E ratio is -1.16. In terms of profitability, HLN's ROE is +0.09%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, HLN is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs AGRX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HLN is priced at $11.07, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HLN's ROE is +0.09%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, HLN is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SISI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SISI has a market cap of 8.9M. Regarding current trading prices, HLN is priced at $11.07, while SISI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SISI's P/E ratio is N/A. In terms of profitability, HLN's ROE is +0.09%, compared to SISI's ROE of -1.41%. Regarding short-term risk, HLN is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs YCBD Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, YCBD has a market cap of 8.6M. Regarding current trading prices, HLN is priced at $11.07, while YCBD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas YCBD's P/E ratio is 0.01. In terms of profitability, HLN's ROE is +0.09%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, HLN is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs IMCC Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, IMCC has a market cap of 8.5M. Regarding current trading prices, HLN is priced at $11.07, while IMCC trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas IMCC's P/E ratio is -2.00. In terms of profitability, HLN's ROE is +0.09%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, HLN is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs NLTX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HLN is priced at $11.07, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HLN's ROE is +0.09%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, HLN is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs SBFMW Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, SBFMW has a market cap of 7.5M. Regarding current trading prices, HLN is priced at $11.07, while SBFMW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas SBFMW's P/E ratio is -0.11. In terms of profitability, HLN's ROE is +0.09%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, HLN is less volatile compared to SBFMW. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs LCI Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HLN is priced at $11.07, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas LCI's P/E ratio is -0.04. In terms of profitability, HLN's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HLN is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.
HLN vs BGXX Comparison
HLN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HLN stands at 50B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, HLN is priced at $11.07, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HLN currently has a P/E ratio of 25.73, whereas BGXX's P/E ratio is -0.76. In terms of profitability, HLN's ROE is +0.09%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, HLN is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for HLN.